AF Statisa collaboration of healthcare leaders and
organizations working to improve the health and well-being of people affected
by atrial fibrillation. AF Stat is raising awareness of
AFib as a complex, costly, progressive and often debilitating disease. It
also is calling for and helping promote a change in attitudes and behaviors to
enhance AFib understanding, diagnosis and management. AF Stat is sponsored by sanofi-aventis
U.S. LLC.More
information can be found at
Summary: Atrial fibrillation (AFib) is a common and serious cardiovascular disease associated with significant morbidity and mortality. Given the incidence, prevalence, and life-threatening complications of AFib increase with age, Medicare is forced to absorb a majority of the substantial clinical and economic burden.
Summary: This document is a call to action that describes gaps and recommends priority actions to enhance the approach to and management of atrial fibrillation and improve patient outcomes.
Summary: Atrial fibrillation (AFib) is a common and serious cardiovascular disease associated with significant morbidity and mortality. Given the incidence, prevalence, and life-threatening complications of AFib increase with age, Medicare is forced to absorb a majority of the substantial clinical and economic burden.
Summary: This document is a call to action that describes gaps and recommends priority actions to enhance the approach to and management of atrial fibrillation and improve patient outcomes.
Summary: Atrial fibrillation (AFib) is a common and serious cardiovascular disease associated with significant morbidity and mortality. Given the incidence, prevalence, and life-threatening complications of AFib increase with age, Medicare is forced to absorb a majority of the substantial clinical and economic burden.
Summary: This document is a call to action that describes gaps and recommends priority actions to enhance the approach to and management of atrial fibrillation and improve patient outcomes.
